000132529 001__ 132529
000132529 005__ 20240229105021.0
000132529 0247_ $$2doi$$a10.1002/hon.2473
000132529 0247_ $$2pmid$$apmid:28840598
000132529 0247_ $$2ISSN$$a0278-0232
000132529 0247_ $$2ISSN$$a1099-1069
000132529 0247_ $$2altmetric$$aaltmetric:24396156
000132529 037__ $$aDKFZ-2018-00213
000132529 041__ $$aeng
000132529 082__ $$a610
000132529 1001_ $$00000-0002-4000-6904$$aBaertsch, Marc-Andrea$$b0
000132529 245__ $$aTherapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
000132529 260__ $$aNew York, NY [u.a.]$$bWiley Interscience$$c2018
000132529 3367_ $$2DRIVER$$aarticle
000132529 3367_ $$2DataCite$$aOutput Types/Journal article
000132529 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659447582_15545
000132529 3367_ $$2BibTeX$$aARTICLE
000132529 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132529 3367_ $$00$$2EndNote$$aJournal Article
000132529 520__ $$aIn multiple myeloma (MM), the synergy between immunomodulatory drugs (IMiDs) and monoclonal antibodies (MABs) has been demonstrated in several pivotal trials. However, disease refractory to either class of compounds remains a major therapeutic challenge. We here report on 3 heavily pretreated MM patients who were refractory to pomalidomide as well as to MABs against CD38 (daratumumab) or CD20 (rituximab), respectively, but who responded to retreatment with the same agents in combination. Responses were durable with PFS of 7, 10 (ongoing), and 30 months from initiation of combination treatment. The combination of IMiDs with MABs directed against MM cell surface antigens can overcome refractoriness to both agents.
000132529 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000132529 588__ $$aDataset connected to CrossRef, PubMed,
000132529 7001_ $$aHundemer, Michael$$b1
000132529 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b2$$udkfz
000132529 7001_ $$aGoldschmidt, Hartmut$$b3
000132529 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b4$$eLast author
000132529 773__ $$0PERI:(DE-600)2001443-0$$a10.1002/hon.2473$$gVol. 36, no. 1, p. 258 - 261$$n1$$p258 - 261$$tHematological oncology$$v36$$x0278-0232$$y2018
000132529 909CO $$ooai:inrepo02.dkfz.de:132529$$pVDB
000132529 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132529 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132529 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000132529 9141_ $$y2018
000132529 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132529 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132529 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132529 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132529 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEMATOL ONCOL : 2015
000132529 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132529 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132529 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132529 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132529 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132529 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132529 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132529 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000132529 9201_ $$0I:(DE-He78)G170-20160331$$kG170$$lExperimentelle Therapien hämatologischer Neoplasien$$x1
000132529 980__ $$ajournal
000132529 980__ $$aVDB
000132529 980__ $$aI:(DE-He78)E010-20160331
000132529 980__ $$aI:(DE-He78)G170-20160331
000132529 980__ $$aUNRESTRICTED